- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07799558
Guided Biofilm Therapy Versus Conventional Polishing for Tooth Re-Staining
Guided Biofilm Therapy Versus Conventional Polishing for Extrinsic Tooth Re-Staining, Patient Comfort, and Procedure Time: A Randomized Split-Mouth Trial
This study compared Guided Biofilm Therapy with conventional polishing in adults with visible extrinsic tooth staining. Each participant received Guided Biofilm Therapy on one side of the mouth and conventional polishing on the other side.
The study evaluated whether the two methods differed in the amount of tooth re-staining after treatment, patient discomfort during the procedures, and total procedure time. Tooth color was measured with a spectrophotometer immediately after treatment, at 1 month, and at 2 months. Patient discomfort was recorded using a visual analog scale, and procedure time was measured with a stopwatch.
A total of 34 participants completed the study.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This randomized split-mouth clinical trial was conducted in adults with visible extrinsic tooth staining. The aim was to compare Guided Biofilm Therapy (GBT) with conventional polishing in terms of post-procedural extrinsic tooth re-staining, patient discomfort, and procedure time.
Each participant received both interventions. One side of the mouth was assigned to GBT and the contralateral side to conventional polishing. The right-left allocation of the interventions was determined by randomization, with the two allocation sequences equally distributed among participants.
In the GBT intervention, dental biofilm was first disclosed and then removed using an air-water-powder system with a low-abrasive erythritol-based powder. Supragingival ultrasonic instrumentation was performed where necessary. In the conventional polishing intervention, supragingival instrumentation was followed by mechanical polishing with a brush and polishing paste.
Tooth color was assessed using a SpectroShade Micro spectrophotometer and the CIELAB color system. Measurements were performed immediately after treatment at baseline (T0), at 1 month (T1), and at 2 months (T2). Color change between assessment periods was calculated using ΔE*ab values.
Patient-reported discomfort was assessed immediately after each half-mouth procedure using a visual analog scale. Total procedure time for each intervention was recorded with a stopwatch.
The primary outcome was color change from immediately after treatment to 2 months. Secondary outcomes included color change from immediately after treatment to 1 month, color change from 1 month to 2 months, patient discomfort, and procedure time.
A total of 34 participants completed all study visits and follow-up assessments.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Erzurum
-
Erzurum, Erzurum, Tyrkia (Türkiye), 25080
- Ataturk University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Age over 18 years.
- Willingness to participate in the study and provision of written informed consent.
- Good general health with no systemic disease.
- Clinical presence of extrinsic staining on tooth surfaces at a level warranting professional polishing.
- Right-handed tooth brushing.
- No professional dental cleaning within the previous 6 months.
Exclusion Criteria:
- Age under 18 years.
- Diagnosis of periodontitis.
- Current smoking.
- Antibiotic use within the previous 3 months.
- Presence of acute periodontal disease.
- Allergy to polishing powders, specifically erythritol.
- Presence of a communicable disease.
- Teeth to be measured with restorations, caries, excessive wear, or structural defects that could affect measurement.
- Active orthodontic treatment.
- Developmental or structural anomalies affecting enamel and potentially increasing susceptibility to extrinsic staining, including hypomineralization, amelogenesis imperfecta, or dentinogenesis imperfecta.
- Severe dental crowding preventing standardized measurements.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Sequence A: Right GBT / Left Conventional Polishing
Participants assigned to Sequence A received Guided Biofilm Therapy on the right half of the mouth and conventional polishing on the left half of the mouth.
Both interventions were performed within the split-mouth study design.
|
Dental biofilm was first disclosed to guide treatment.
Supragingival biofilm and extrinsic staining were then removed using an air-water-powder system with a low-abrasive erythritol-based powder.
Supragingival ultrasonic instrumentation was performed where necessary, followed by final surface control.
Andre navn:
Supragingival instrumentation was performed as needed, followed by mechanical polishing with a prophylaxis brush and polishing paste at 2500 to 3000 rpm.
The procedure was completed with final surface control.
Andre navn:
|
|
Eksperimentell: Sequence B: Right Conventional Polishing / Left GBT
Participants assigned to Sequence B received conventional polishing on the right half of the mouth and Guided Biofilm Therapy on the left half of the mouth.
Both interventions were performed within the split-mouth study design.
|
Dental biofilm was first disclosed to guide treatment.
Supragingival biofilm and extrinsic staining were then removed using an air-water-powder system with a low-abrasive erythritol-based powder.
Supragingival ultrasonic instrumentation was performed where necessary, followed by final surface control.
Andre navn:
Supragingival instrumentation was performed as needed, followed by mechanical polishing with a prophylaxis brush and polishing paste at 2500 to 3000 rpm.
The procedure was completed with final surface control.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Tooth Color From Immediately After Treatment to 2 Months Assessed by CIELAB ΔE*ab Using a SpectroShade Micro Spectrophotometer
Tidsramme: Immediately after treatment (Day 1) and at 2 months
|
Tooth color was measured using a SpectroShade Micro spectrophotometer according to the CIELAB color system.
Color change between immediately after treatment (T0) and 2 months (T2) was calculated as ΔEab using the formula: ΔEab = [(ΔL*)² + (Δa*)² + (Δb*)²]^(1/2).
ΔEab is a continuous color-difference measure, with 0 indicating no color difference and higher values indicating greater color change.
Therefore, lower ΔEab values indicate greater color stability.
|
Immediately after treatment (Day 1) and at 2 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Tooth Color From Immediately After Treatment to 1 Month Assessed by CIELAB ΔE*ab Using a SpectroShade Micro Spectrophotometer
Tidsramme: Immediately after treatment (Day 1) and at 1 month
|
Tooth color was measured using a SpectroShade Micro spectrophotometer according to the CIELAB color system.
Color change between immediately after treatment (T0) and 1 month (T1) was calculated as ΔEab using the formula: ΔEab = [(ΔL*)² + (Δa*)² + (Δb*)²]^(1/2).
ΔEab is a continuous color-difference measure, with 0 indicating no color difference and higher values indicating greater color change.
Therefore, lower ΔEab values indicate greater color stability.
|
Immediately after treatment (Day 1) and at 1 month
|
|
Change in Tooth Color From 1 Month to 2 Months
Tidsramme: At 1 month and 2 months
|
Tooth color was measured using a SpectroShade Micro spectrophotometer according to the CIELAB color system.
Color change between 1 month (M1) and 2 months (M2) was calculated as ΔE*ab using the formula: ΔE*ab = [(ΔL*)² + (Δa*)² + (Δb*)²]^(1/2).
Lower ΔE*ab values indicate less color change.
|
At 1 month and 2 months
|
|
Patient-Reported Discomfort Assessed Using a 10-cm Visual Analog Scale
Tidsramme: Immediately after completion of each half-mouth intervention (Day 1)
|
Patient-reported discomfort was assessed immediately after each half-mouth procedure using a 10-cm visual analog scale ranging from 0 to 10, where 0 indicated no discomfort and 10 indicated unbearable discomfort.
The score reflected the overall perception of pain or sensitivity, heat, pressure or vibration, and discomfort related to water spray or aerosol.
Lower scores indicate greater patient comfort.
|
Immediately after completion of each half-mouth intervention (Day 1)
|
|
Total Procedure Time Measured Using a Digital Stopwatch
Tidsramme: Periprocedural
|
Total procedure time for each intervention was recorded using a digital stopwatch.
Timing began with the first clinical step of the relevant intervention and ended after completion of the final surface check.
Patient preparation, isolation, and oral hygiene instruction were excluded.
Procedure time was recorded in minutes and seconds, with shorter times indicating greater procedural efficiency.
|
Periprocedural
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Recep Orbak, DDS, PhD, Ataturk University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 926
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .